Latest news with #CRSP
Yahoo
02-07-2025
- Business
- Yahoo
$1,000 in the Vanguard Value Index Fund ETF Could Turn Into $1,900
Value stocks have trailed growth stocks recently. You should use past returns with caution. Nonetheless, these can serve as a starting point when modeling future returns. 10 stocks we like better than Vanguard Index Funds - Vanguard Value ETF › No one has the ability to accurately predict the future, of course. That certainly applies to investments. However, you can project how much your initial investment will become based on an assumed rate of return and your intended holding period. If you were to invest $1,000 in the Vanguard Value Index Fund ETF (NYSEMKT: VTV), how much would you have after five years? This exchange-traded fund (ETF), with nearly $190 billion in assets as of May 31, is popular with investors. But let's have an overview, because it's advisable to understand the ETF before investing any money. The Vanguard Value Index Fund ETF tracks the CRSP US Large Cap Value Index, which includes 330 companies with a median market capitalization of more than $130 billion. The ETF has more than half of its funds invested in the financial (22.9%), industrial (16.2%), and healthcare (14.3%) sectors. As the name suggests, it seeks to include value stocks rather than growth stocks. You can see this by comparing the price-to-earnings (P/E) ratio since that's a common valuation metric. At the end of May, the stocks in the index and ETF had an average P/E ratio of 18.9 versus 37.2 for the Vanguard Growth ETF. Growth stocks have vastly outperformed value stocks over various time periods. The Vanguard Value Index Fund ETF returned 13.9% over the last five years through May 31. During this time, the Vanguard Growth ETF returned an annualized 17.1%. Notably, since both invest passively, tracking their respective indexes, they have low fees. The Vanguard Growth ETF has an expense ratio of just 0.04%, or $4 annually per $10,000 invested. That's much lower than the average expense ratio of 0.88% for similar funds, according to Vanguard. The expense ratio is an important consideration for investors. The lower the ratio, the more money investors get to keep. That translates into a higher return. With knowledge about the ETF's stock composition, fees, and past returns, it's time to look at future rates of return. As the well-worn saying goes, past performance is no guarantee of future results. Still, it's a good base assumption that you can adjust upward and downward. If the fund returns the same 13.9% over the next five years, your $1,000 investment would grow to about $1,917. That's nearly doubling your initial stake. With the economic uncertainty amid geopolitical tensions and the uncertain effects of global economies, it seems prudent to model a lower rate of return. Assuming a 5% annualized return over the next five years, that $1,000 would turn into $1,276. That's not a much higher return than the roughly 4% yield you could get on the risk-free U.S. Treasury's five-year note. What if the ETF matched the previous five years' growth ETF return? After all, while growth stocks have done well lately, that doesn't mean they'll continue to outpace value stocks. In that scenario, your initial $1,000 investment would more than double to $2,202. And, under a very optimistic scenario, if the ETF returns 25% per year, you'd more than triple your funds to $3,052. Before you buy stock in Vanguard Index Funds - Vanguard Value ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vanguard Index Funds - Vanguard Value ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $722,181!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $968,402!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vanguard Index Funds-Vanguard Growth ETF and Vanguard Index Funds-Vanguard Value ETF. The Motley Fool has a disclosure policy. $1,000 in the Vanguard Value Index Fund ETF Could Turn Into $1,900 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
CRISPR Therapeutics AG (CRSP): A Bull Case Theory
We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap's Substack. In this article, we will summarize the bulls' thesis on CRSP. CRISPR Therapeutics AG (CRSP)'s share was trading at $41.52 as of 11th June. CRSP's trailing and forward P/E were 22.55 and 23.36 respectively according to Yahoo Finance. A scientist peering into a microscope, researching the next gene therapy breakthrough. CRISPR has re-entered the spotlight thanks to a groundbreaking case where the technology was used to treat Baby KJ, born with a severe genetic liver disorder caused by a CPS1 enzyme deficiency. With only a 50% survival rate in infancy, traditional treatment included heavy medication and a strict low-protein diet. But researchers rapidly developed a personalized CRISPR therapy that KJ has now received three times, allowing him to eat a regular diet and significantly reduce medication use. This marks a major milestone not only for KJ but for the broader gene-editing landscape. At its core, CRISPR-Cas9 was originally a bacterial defense mechanism that evolved to recognize and cut viral DNA. Scientists have since repurposed this system, using modified guide RNAs and engineered Cas9 proteins to target human DNA with remarkable precision. In most therapeutic uses, CRISPR creates double-stranded breaks that are imperfectly repaired by the body—helpful for knocking out malfunctioning genes, as seen with CASGEVY, the FDA-approved therapy for sickle cell disease and beta thalassemia. KJ's case went further, employing 'base editing' to fix a single-letter DNA error using a deaminase-modified CRISPR complex that swapped an adenine for a guanine, correcting the mutation without a DNA break. This was delivered via lipid nanoparticles (LNPs), offering dosing flexibility over traditional viral vectors. The success not only validates the science behind base editing but also uplifts companies like Beam, CRISPR Therapeutics, and Intellia after years of market declines. It also spotlights Danaher's Aldevron and Acuitas Therapeutics, whose platforms were instrumental in the therapy's development, underscoring the growing viability of personalized gene medicine. We previously covered a bullish thesis on CRISPR Therapeutics (CRSP) from wallstreetbets by MADD-Scientis, emphasizing Casgevy's revenue potential, strong cash runway, and optionality in oncology and cardiology. Since the coverage, the stock price has appreciated by roughly 1.3%. Two Natural Cap's thesis adds depth by spotlighting CRSP's role in a groundbreaking base-editing therapy, reinforcing the platform's adaptability. Both cases point to CRSP's leadership in curative gene editing. CRISPR Therapeutics AG (CRSP) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held CRSP at the end of the first quarter which was 27 in the previous quarter. While we acknowledge the risk and potential of CRSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-06-2025
- Business
- Yahoo
This ETF Could Turn Ordinary Savings Into $1 Million
Investing in ETFs can help you build wealth with next to no effort. A growth ETF is designed to earn above-average returns over time. It's possible to earn over $1 million with just $200 per month. 10 stocks we like better than Vanguard Index Funds - Vanguard Growth ETF › Investing in the stock market is one of the best ways to generate long-term wealth, but you don't need to be rich to get started. In fact, contributing even a couple hundred dollars per month can add up to $1 million or more over time. However, where you invest will make all the difference in how much you're able to earn. Exchange-traded funds (ETFs) require next to no effort on your part, and they can minimize risk while helping turn everyday savings into life-changing wealth. And there's one ETF, in particular, that could turn $200 per month into $1 million. An ETF is a collection of stocks bundled together into a single investment. When you buy just one share of an ETF, you'll gain exposure to every stock included in that fund. Some funds contain a few dozens stocks from one industry, while others may include hundreds or even thousands of stocks across all sectors of the market. If you're looking to earn above-average returns with minimal effort, the Vanguard Growth ETF (NYSEMKT: VUG) may be a smart choice. This fund tracks the CRSP U.S. Large-Cap Growth Index, and it contains 166 stocks from all 11 market sectors. A key advantage of this ETF is its balance of risk and reward. It only contains large-cap stocks, which are companies with a market capitalization of at least $10 billion. A few of the largest holdings -- such as Apple, Microsoft, and Nvidia -- are also considered megacap stocks with a market cap of more than $200 billion. Large- and megacap stocks can carry less risk than smaller companies, as they're industry-leading behemoths that are more likely to survive periods of market turbulence. At the same time, though, this fund only contains stocks with the potential for above-average growth -- making it easier to build substantial wealth over time. It's important to note that nobody knows exactly how stocks will perform going forward, especially in the coming weeks or months. But historically, the market itself has earned an average annual rate of return of around 10%, meaning all the annual highs and lows have averaged out to roughly 10% per year. Over the last decade, the Vanguard Growth ETF has earned an average rate of return of 15.29% per year, while its average return since its inception in 2004 is 11.51% per year. For simplicity's sake, let's assume that this fund earns an average return of 12% per year going forward. If you were to invest $200 per month at that rate, here's approximately how much you could accumulate depending on how many years you let your money grow: Number of Years Total Portfolio Value 20 $173,000 25 $320,000 30 $579,000 35 $1,036,000 Data source: Author's calculations via In this scenario, it would take around 35 years of consistent investing to turn $200 per month into at least $1 million. However, you could reach that goal sooner with slightly higher monthly contributions or a higher average annual return. For example, if you begin contributing $400 per month, all other factors remaining the same, you could reach $1 million around six years sooner. Similarly, if this fund were to earn a 15% average annual return, as it has over the past decade, you could earn $1 million in around 30 years with just $200 per month or 25 years with $400 per month. No matter how much you're investing or what kind of returns you're earning, getting started now is one of the most important factors in building wealth. By investing consistently for as many years as possible, you could earn more than you might think with the Vanguard Growth ETF. Before you buy stock in Vanguard Index Funds - Vanguard Growth ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vanguard Index Funds - Vanguard Growth ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Katie Brockman has positions in Vanguard Index Funds-Vanguard Growth ETF. The Motley Fool has positions in and recommends Apple, Microsoft, Nvidia, and Vanguard Index Funds-Vanguard Growth ETF. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. This ETF Could Turn Ordinary Savings Into $1 Million was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
30-05-2025
- Business
- Business Insider
Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
In a report released on May 20, Salim Syed from Mizuho Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $85.00. The company's shares opened today at $37.00. Confident Investing Starts Here: Syed covers the Healthcare sector, focusing on stocks such as Vaxcyte, Wave Life Sciences, and Cytokinetics. According to TipRanks, Syed has an average return of -9.6% and a 35.89% success rate on recommended stocks. Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $67.63, an 82.78% upside from current levels. In a report released yesterday, Citizens JMP also reiterated a Buy rating on the stock with a $86.00 price target. CRSP market cap is currently $3.39B and has a P/E ratio of -8.19. Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year. Most recently, in February 2025, John Greene, a Director at CRSP bought 7,000.00 shares for a total of $313,880.00.
Globe and Mail
27-05-2025
- Business
- Globe and Mail
Is the Vanguard Mega Cap Growth ETF Your Ticket to Mega Returns?
The Vanguard Mega Cap Growth ETF (NYSEMKT: MGK) does exactly what its name implies: It buys the largest growth companies. That's been a winning investment plan for a number of years, but investors need to consider the portfolio of this exchange-traded fund (ETF) a bit more deeply before making a new commitment today. Here's why the Vanguard Mega Cap Growth ETF could be a problem for your portfolio if you don't understand what it is you are buying. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » What does the Vanguard Mega Cap Growth ETF do? The Vanguard Mega Cap ETF tracks the CRSP US Mega Cap Growth Index. Some complex math goes into the index, but the outcomes are pretty simple to understand. It uses market caps to determine what stocks count as megacaps. It factors in earnings growth, return on assets, and the investment-to-assets ratio to assign companies to the growth category. The companies that are found in both groups get into the ETF. This isn't a good or bad approach, per se. What it does is put investors into the stocks that are likely to be the most popular during market upturns. That can feel pretty good in a bull market. However, there's a problem to consider because buying the largest, most popular companies is also likely to lead investors to be overweight in a small number of stocks. For example, just three stocks make up more than a third of this Vanguard ETF's portfolio today. All three fall into the technology sector. They are names you likely know: Apple (NASDAQ: AAPL), Microsoft (NASDAQ: MSFT), and Nvidia (NASDAQ: NVDA). But that's not the end of the story, because technology as a sector makes up a huge 60% of the ETF's assets right now. When the market turns lower, the largest and most popular stocks and sectors are likely to lead the way down. Which means that bear markets and corrections are likely to be particularly painful if you own the Vanguard Mega Cap Growth ETF. What has happened in 2025? Which is why it is interesting to consider 2025 as a stress test. Comparing the Vanguard Mega Cap Growth ETF to the broader S&P 500 index (SNPINDEX: ^GSPC) and an equal-weighted version of the S&P 500 index, the Invesco S&P 500 Equal Weight ETF (NYSEMKT: RSP), is illuminating. MGK Total Return Level data by YCharts. Notice that the Vanguard ETF fell furthest during this turbulent period. The more diversified S&P 500 index, which itself leans toward large caps and is market-cap weighted, fell in the middle, performance wise. And the Invesco S&P 500 Equal Weight ETF, which gives each stock in the S&P 500 index the same weighting (meaning that each company has the same opportunity to affect performance), was the best performer. In this period, giving the largest, and likely recently best-performing, companies an overweight status turned into a liability. To be fair, if you look over a longer period of time, the Vanguard ETF is the clear winner. And it rebalances quarterly, so it is fairly quick to change when the market leaders shift. But investors shouldn't go in without understanding the risk that focusing on the biggest and the best can lead to worse drawdowns when the market shifts from a bull to a bear. MGK Total Return Level data by YCharts. There are two big takeaways here There's nothing wrong with buying the Vanguard Mega Cap Growth ETF as long as you understand what it is you own. History suggests that you will do particularly well in good markets. Most investors will see that as a win. That said, you need to go in knowing that downturns could be particularly difficult times for this ETF. And you'll either need to grit your teeth and hold for the long term or, perhaps better, pair the Vanguard Mega Cap ETF with another investment that will perform better during downturns. That way, you have something else to look at besides the red ink the Vanguard Mega Cap Growth ETF is putting up. Should you invest $1,000 in Vanguard World Fund - Vanguard Mega Cap Growth ETF right now? Before you buy stock in Vanguard World Fund - Vanguard Mega Cap Growth ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vanguard World Fund - Vanguard Mega Cap Growth ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor 's total average return is957% — a market-crushing outperformance compared to167%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
